These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31463563)

  • 1. What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial.
    Schennach R; Riedel M; Obermeier M; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Spellmann I; Musil R; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2020 Sep; 270(6):661-671. PubMed ID: 31463563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of relapse in the year after hospital discharge among patients with schizophrenia.
    Schennach R; Obermeier M; Meyer S; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    Psychiatr Serv; 2012 Jan; 63(1):87-90. PubMed ID: 22227766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial.
    Huhn M; Leucht C; Rothe P; Dold M; Heres S; Bornschein S; Schneider-Axmann T; Hasan A; Leucht S
    Eur Arch Psychiatry Clin Neurosci; 2021 Mar; 271(2):293-302. PubMed ID: 32062728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.
    Bäuml J; Pitschel-Walz G; Volz A; Lüscher S; Rentrop M; Kissling W; Jahn T
    Schizophr Bull; 2016 Jul; 42 Suppl 1(Suppl 1):S62-70. PubMed ID: 26955982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year functional outcomes of naturalistically treated patients with schizophrenia.
    Spellmann I; Riedel M; Schennach R; Seemüller F; Obermeier M; Musil R; Jäger M; Schmauß M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
    Psychiatry Res; 2012 Aug; 198(3):378-85. PubMed ID: 22421065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
    Takeuchi H; Siu C; Remington G; Fervaha G; Zipursky RB; Foussias G; Agid O
    Neuropsychopharmacology; 2019 May; 44(6):1036-1042. PubMed ID: 30514883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
    Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
    Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low treatment adherence with antipsychotics is associated with relapse in psychotic disorders within six months after discharge.
    Laan W; van der Does Y; Sezgi B; Smeets HM; Stolker JJ; Wit NJ; Heerdink ER
    Pharmacopsychiatry; 2010 Aug; 43(6):221-4. PubMed ID: 20503150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year follow up of patients with first-episode schizophrenia spectrum disorder from an early intervention service: Predictors of clinical remission and functional recovery.
    Chan SKW; Hui CLM; Chang WC; Lee EHM; Chen EYH
    Schizophr Res; 2019 Feb; 204():65-71. PubMed ID: 30126816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.
    Schennach R; Riedel M; Obermeier M; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ
    Psychiatr Q; 2012 Jun; 83(2):187-207. PubMed ID: 22038270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trajectories after first-episode psychosis: Complement to ambiguous outcomes of long-term antipsychotic treatment by exploring a few hidden cases.
    Liu CC; Lin YT; Liu CM; Hsieh MH; Chien YL; Hwang TJ; Hwu HG
    Early Interv Psychiatry; 2019 Aug; 13(4):895-901. PubMed ID: 29927087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders.
    Helldin L; Kane JM; Karilampi U; Norlander T; Archer T
    Schizophr Res; 2007 Jul; 93(1-3):160-8. PubMed ID: 17395430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.